Objective This meta-analysis aims to investigate the diagnostic performance of serum homocysteine (Hcy) as a biomarker for diabetic nephropathy (DN).
Introduction
Diabetic nephropathy (DN) is one of the major complications of diabetic microangiopathy and the main cause of end-stage renal disease [1] . Early diagnosis and treatment of DN is of great important for the prognosis. At present, quantitative urinary microalbumin is generally used in the diagnosis of DN clinically [2, 3] . However, Urinary albumin levels are, however, affected by urinary tract infections, fever, congestive heart failure and other relevant disease, strenuous exercise is amongst other factors that can alter the levels detected [2, 4] . Therefore, the quantification of urinary microalbumin in the diagnosis of DN is not sensitive. Recently, several studies have evaluated serum Hcy as biomarker in the diagnosis of DN [5] [6] [7] . However, the diagnostic performance of serum Hcy for DN diagnosis was not consistent across studies because of small sample sizes and different serum Hcy detection methods. Therefore, in order to further evaluate the diagnostic performance of serum Hcy for DN diagnosis, we performed this meta-analysis by pooling the relevant studies.
Material and Methods

Publication searching in the electronic databases
Studies associated with serum Hcy level and DN were systematically searched in the electronic databases of; Pubmed, Cochrane Library, Embase, Web of science CNKI and CBM. The electronic searching text words were as follows: diabetic nephropathy/DN; diabetic kidney disease; homocysteine/Hcy. The reference of the potential relevant publications was evaluated in order to find additional suitable studies. The publication searching procedure was performed by two reviewers independently and made cross check.
Publication inclusion and exclusion criteria
To be included in the study, the publications had to have: (1) patients that were diagnosed with DN according to WHO standards; (2) a correct detection method for serum Hcy levels; (3) data of true positive, false positive, false negative and true negative which was used for pooling the diagnostic effect size. The study exclusion criteria were: (1) other types nephropathy; (2) duplicates published data or studies; (3) not enough data can be extracted from the original studies.
Statistical analysis
The data was analyzed by Meta DiSc1.4 (http://www. biomedsearch.com) statistical software. I 2 test was performed before pooling the data in order to evaluate the statistical heterogeneity across the included 18 publications. When I 2 >50%, the statistical heterogeneity was deem as not statistically significant and data pooled through fixed effect model. Otherwise, random effect model was used in pooling the data. A p value less than 0.05 was statistical different.
Results
Main characteristics of the original included studies
In total 18 publications relevant to serum Hcy level and DN were included in the meta-analysis. The electronic searching procedure of the relevant publications is showed by Figure 1 . The main characteristics of the 18 studies are demonstrated in Table 1 .
Heterogeneity evaluation
Before pooling the data, we first evaluated the statistical heterogeneity across the included 18 publications. The I 2 test demonstrated significant statistical heterogeneity across the included 18 studies for the effect size of diagnostic, Table 2 . 
Pooled diagnostic sensitivity
The diagnostic sensitivity was pooled through random effect methods because of significant statistical heterogeneity across the included publications. The pooled diagnostic sensitivity was 0.76 with the 95% confidence interval (95%CI) of 0.74-0.78, Figure 2 .
Pooled diagnostic specificity
The pooled diagnostic specificity of serum Hcy as biomarker for DN was 0.84(95%CI:0.82-0.86) in the random effect model, Figure 3 .
Pooled +LR and -LR
Because of significant heterogeneity in the effect size of +LR and -LR (I 2 >50%), the +LR and -LR were pooled by random effect model. The combined +LR and -LR were 5.05(95%CI:3.52-7.24) , Figure 4 and 0.27(95%CI:0.19-0.39) respectively, Figure 5 . 
Pooled diagnostic DOR
The diagnostic DOR was also pooled in random effect method (I 2 >50%). The pooled diagnostic DOR was 21.68 with it corresponding 95% CI of 11.15to 42.14, Figure 6 .
Pooled diagnostic SROC and AUC
The pooled SROC is showed in Figure 6 . The combined AUC was 0.90 for serum Hcy as biomarker in diagnosis of DN.
Subgroup analysis
We performed subgroup analysis according to Hcy cut off value and Hcy examine method. The pooled effect size is showed in Table 3 .
Discussion
With the improvement of people's living standard, a change of life style and the aging of society, the incidence of diabetes mellitus (DM) is increasing year by year in China [22] . It was reported that there were about 92.4 million diabetic patients in China, which had become the largest diabetic country in the world [23] . Diabetic nephropathy (DN), as a common microvascular complication of diabetes mellitus, is one of the most common causes of end-stage renal disease [24] , and also one of the significant causes of death and disability of patients suffering from diabetes mellitus. Early diagnosis and proper management of DN can delay the development of diabetic nephropathy and improve prognosis [25, 26] . At present, DN diagnosis is generally based on the quantitatification of urinary microalbumin levels [27, 28] . However, quantitative urinary microalbumin can be affect by many diseases. Therefore, high sensitivity and specificity biological markers with good diagnostic performance were needed for DN early diagnosis.
Homocysteine (Hcy) is a sulfhydryl-containing nonessential amino acid, which is the intermediate product of methyl sulfur amino acid metabolism. It is mainly excreted by kidney. Hcy can directly cause vascular endothelial cell injury and smooth muscle cell proliferation, leading to the development of DN. Studies have shown that hyperhomocysteinemia is closely related to hypertension and atherosclerosis, which was an independent risk factor for vascular diseases and DN [29, 30] .
In our present work, we included 18 studies relevant to serum Hcy as serological marker for DN diagnosis and found that serum Hcy was a promising serological marker for DN diagnosis. The diagnosis sensitivity and specificity was relative high which indicated serum Hcy had good diagnosis performance for DN. However, there are obvious limitations for the present meta-analysis. Firstly, a significant statistical heterogeneity was found among the included studies. The obvious statistical heterogeneity can reduce the statistical power and limit its clinical usage. Secondly, only studies published in English or Chinese were screened in the electronic databases which may lead to publication bias.
Conclusion
Based on the present publications, the serum Hcy was a promising serological marker for DN diagnosis. However, with obvious limitations of statistical heterogeneity and potential publication bias, more relevant studies were needed to further evaluate its diagnostic efficacy as serological marker for DN.
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